Your session is about to expire
← Back to Search
Radium-223 + Docetaxel for Prostate Cancer
Study Summary
This trial is comparing the efficacy of adding Radium-223 to Docetaxel chemotherapy versus Docetaxel chemotherapy alone in men with metastatic hormone-refractory prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 29 Patients • NCT02278055Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have swelling in my groin, penis, or legs due to cancer.I haven't taken any experimental cancer treatments or other cancer therapies in the last 4 weeks.I have severe urinary or rectal symptoms due to my cancer.Any side effects from my previous treatments are mild.I have had chemotherapy for prostate cancer after it became resistant to hormonal therapy.I have undergone four or more cancer treatments for advanced prostate cancer.I have experienced severe side effects from docetaxel.I have not had blood transfusions or growth factors in the last 4 weeks.I haven't taken any medications or supplements that affect PSA levels in the last 4 weeks.You have a serious illness or medical condition that the doctor thinks would make this study too risky for you.I have Crohn's disease or ulcerative colitis and have not had my colon removed.I do not have an active cancer other than non-melanoma skin, non-invasive bladder cancer, or other non-invasive cancers.I have a diagnosed bone marrow disorder.I do not have any infections that are not responding to treatment.My cancer has grown by 20% or more, or I have new cancer spots since starting treatment.You have been diagnosed with advanced prostate cancer that is getting worse based on certain medical tests.My testosterone levels are below 50 ng/dL, and I am on hormone therapy unless I've had an orchiectomy.I have received treatment with medication targeting bones before.I had external beam radiotherapy in the last 4 weeks.I need to start radiation therapy soon.I may have had docetaxel or abiraterone for my cancer, but it's not counted as a prior treatment line.I do not have an active HIV, Hepatitis B, or Hepatitis C infection.My prostate cancer diagnosis was confirmed through lab tests.I am fully active and can carry on all my pre-disease activities without restriction.I have at least 3 lung or liver metastases or one larger than 2 cm.My bone disease has worsened or I have two or more new bone lesions.I have two or more bone lesions.I am a man aged 18 or older.My recent tests show my organs are functioning well.I have spinal cord compression confirmed by symptoms or MRI.I have severe heart failure.
- Group 1: Docetaxel
- Group 2: Docetaxel with Radium-223
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any current openings for participants in this experiment?
"The clinical trial is still recruiting patients and the most recent information available was edited on March 30th, 2022. The original posting date for this trial was June 19th, 2018."
Are there any other examples of Radium-223 being used in a clinical capacity?
"There are currently 344 ongoing clinical trials researching the effects of Radium-223. Out of these, 132 are in Phase 3. The city with the most trials is Fuzhou, Fujian but there are 23106 locations running studies for Radium-223 globally."
Is this trial being conducted in more than one state?
"Patients are currently being accepted at the Houston Methodist Hospital in Houston, Texas; MD Anderson Cancer Center at Cooper in Camden, Illinois; and Rush University Medical Center in Chicago, Minnesota. In addition, there are 38 other medical facilities where patients can enroll."
What cancers has Radium-223 been effective in treating?
"Radium-223 is an effective treatment for malignant neoplasms, advance directives, and sarcoma."
How does Radium-223 impact patients negatively?
"Radium-223's safety was given a 3 because there is both efficacy and safety data from multiple sources."
How many participants are included in this clinical trial?
"That is correct, the information on clinicaltrials.gov does show that this particular trial is looking for patients at the moment. The original posting was on 6/19/2018 and there have been updates as recently as 3/30/2022. They are searching for 738 participants in total, to be recruited from 38 different locations."
Share this study with friends
Copy Link
Messenger